Medical News
On August 5, Neowise Biotechnology, Co., Ltd. (Suzhou) announced that the Investigational New Drug (IND) application for its self-developed, PRAME-targeting autologous TCR-T cell therapy candidate product NW-101C injection has received tacit approval from the National Medical Products Administration (NMPA) for clinical trials. The NW-101C injection is the first TCR-T cell therapy candidate product targeting the PRAME antigen in China to be approved for clinical research.On August 5, Renfu Pharmaceutical announced that HW241045 tablets, developed by its wholly-owned subsidiary Wuhan Renfu Innovative Drug Research and Development Center Co., Ltd., received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The approval allows the drug to proceed with clinical trials for the indication of idiopathic pulmonary fibrosis. HW241045 tablets are classified as Category 1 chemical drugs, and currently, no drugs targeting the same point have been approved for marketing worldwide.Recently, the National Medical Products Administration approved the listing of Shenpu Granules, a Class 1.1 traditional Chinese medicine innovation drug submitted by Jiangsu Kangyuan Pharmaceutical Co., Ltd., providing a new treatment option for patients with chronic pelvic pain caused by sequelae of pelvic inflammatory disease, who are identified in traditional Chinese medicine as having the pattern of damp-heat and blood stasis.On August 5, Chia Tai Tianqing announced that TQC3302 Inhalation Spray, a new Category 2.3 modified drug for chronic obstructive pulmonary disease (COPD) developed by the company, received its first clinical approval. TQC3302 is a triple combination formulation of ICS (inhaled corticosteroid), LAMA (long-acting anticholinergic), and LABA (long-acting β2 receptor agonist) developed based on Chia Tai Tianqing's proprietary soft mist inhalation technology platform.Investment and Financing in Pharmaceuticals
Recently, Chengdu Zeling Biopharmaceutical Technology Co., Ltd. announced the completion of nearly 400 million RMB in financing. This round of financing was led by Qiming Venture Partners, with participation from Gaorong Capital, Jiyuan Capital, Qiji Investment, FiveSource Capital, and Zhongyuan Investment. Sichuan Biomedical Industry Group continued its investment. The funds from this round of financing will be mainly used to advance multiple innovative drugs with global competitiveness into pivotal Phase III clinical trials and to support the continuous expansion of new R&D pipelines.Technology-Driven Drug ResearchRecently, Mikala Egeblad and Jose M. Adrover's team from Cold Spring Harbor Laboratory in the United States published an article in Nature titled "Neutrophils drive vascular occlusion, tumour necrosis and metastasis," revealing a new mechanism of tumor necrosis: neutrophils produce NETs that trigger vascular occlusion, leading to polymorphic necrosis and tumor metastasis. This indicates that tumor necrosis is not necessarily a passive product of tumor growth and nutrient depletion, and that tumor metastasis can be suppressed by intervening in the production of NETs.[1]Adrover, J.M., Han, X., Sun, L. et al. Neutrophils drive vascular occlusion, tumour necrosis and metastasis. Nature (2025). https://doi.org/10.1038/s41586-025-09278-3
